Form 4 for PHAT Phathom Pharmaceuticals, Inc.
Accepted 2024-07-17 00:00:00 ET · period of report 2024-07-15 · accession 0000950170-24-084179 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-07-17 | 2024-07-15 | PHAT | Curran Terrie | Pres, Chief Executive, Dir | S - Sale | $11.72 | -33.8K | 377.7K | -8% | -$396.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-15 | S | D | 33,848 | $11.72 | 377,734 | D | — | — | (F2) Includes 798 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2024. |